Summary
We envision a radically new technology for in-vivo bioresorbable chemical sensing, where optical devices, power and light sources, synthetic receptors - made out of materials that completely dissolve with biologically benign byproducts in biofluids - will be developed and integrated together. The sensing system, the size of 1 EuroCent, will be coated by a long-lived biocompatible polymer designed with on-demand degradation, then implanted in the body to monitor in-vivo, in-situ, and in real-time a chemotherapeutic drug, doxorubicin, commonly used to treat cancer; the system is then fully and safely RESORBed once no more needed using an external temperature-trigger that initiates the dissolution of the protecting coating and, in turn, of the system, avoiding device-retrieval surgery that may cause tissue lesion/infection. The general objective is to demonstrate fabrication, operation (2 months) in-vivo and in real-time - then dissolution - of such a bioresorbable chemical sensing system for the detection of doxorubicin in an animal model. This will break a new ground in in-situ monitoring of chemotherapeutic drug enabling – for the first time – a fine tuning of the drug dose at the tumor site, increasing patient survival rate. Being aware of the project risks, we have broken down the general into different specific objectives, identified a set of Key Performance Indicators, alternative material synthesis/device fabrication techniques, mitigation measures to tackle major risks. The RESORB technology truly represents the foundation of a future technology for personalized medicine, enabling to address a number of medical issues for which continuous and localized monitoring of specific analytes (i.e., biomarkers and drugs) in-vivo for a prescribed time is of chief importance, e.g., acute trauma treatment, post-surgery sepsis, drug therapeutic profiling, and other, all examples for which ex-situ analysis of biofluids has proved to be not fully adequate for clinical needs.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101046946 |
| Start date: | 01-04-2022 |
| End date: | 31-03-2025 |
| Total budget - Public funding: | 2 606 250,00 Euro - 2 606 250,00 Euro |
Cordis data
Original description
We envision a radically new technology for in-vivo bioresorbable chemical sensing, where optical devices, power and light sources, synthetic receptors - made out of materials that completely dissolve with biologically benign byproducts in biofluids - will be developed and integrated together. The sensing system, the size of 1 EuroCent, will be coated by a long-lived biocompatible polymer designed with on-demand degradation, then implanted in the body to monitor in-vivo, in-situ, and in real-time a chemotherapeutic drug, doxorubicin, commonly used to treat cancer; the system is then fully and safely RESORBed once no more needed using an external temperature-trigger that initiates the dissolution of the protecting coating and, in turn, of the system, avoiding device-retrieval surgery that may cause tissue lesion/infection. The general objective is to demonstrate fabrication, operation (2 months) in-vivo and in real-time - then dissolution - of such a bioresorbable chemical sensing system for the detection of doxorubicin in an animal model. This will break a new ground in in-situ monitoring of chemotherapeutic drug enabling – for the first time – a fine tuning of the drug dose at the tumor site, increasing patient survival rate. Being aware of the project risks, we have broken down the general into different specific objectives, identified a set of Key Performance Indicators, alternative material synthesis/device fabrication techniques, mitigation measures to tackle major risks. The RESORB technology truly represents the foundation of a future technology for personalized medicine, enabling to address a number of medical issues for which continuous and localized monitoring of specific analytes (i.e., biomarkers and drugs) in-vivo for a prescribed time is of chief importance, e.g., acute trauma treatment, post-surgery sepsis, drug therapeutic profiling, and other, all examples for which ex-situ analysis of biofluids has proved to be not fully adequate for clinical needs.Status
SIGNEDCall topic
HORIZON-EIC-2021-PATHFINDEROPEN-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
